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In 2003, the Nebraska Public Health Laboratory tested more than 10,371 serum and 516 cerebral spinal fluid
specimens. Results showed that without performing the interfering factors screen for specimens in the low
positive index value range of >1.1 to <3.5, a false positivity rate of 6.5% would have been realized.
Human West Nile virus (WNV)-caused infections in the
United States were first recognized in New York during the
summer of 1999 (6). In 2003, the Nebraska Public Health
Laboratory (NPHL) commenced WNV-specific immunoglob-
ulin M (IgM) antibody testing on serum and cerebral spinal
fluid (CSF) specimens. The reagent pack of the Focus Diag-
nostics flavivirus-specific IgM antibody capture enzyme-linked
immunosorbent assay (MAC-ELISA), consisting of analyte-
specific reagents (ASR), was used. Early in the WNV testing
season, Nebraska state epidemiologists randomly selected 10
positive specimens, from seven patients, to send to the Centers
for Disease Control and Prevention (CDC) for confirmation.
The CDC MAC-ELISA and/or the plaque reduction neutral-
ization test (PRNT) found that 4 of 10 (40%) specimens sub-
mitted, within the positive index value range of 1.1 to 3.5,
were not confirmed and were reported as being negative or
equivocal or needing a second draw. Because of the problems
of interfering factors (IF) inherent in MAC-ELISA coupled
with the CDC’s discordant results, the NPHL decided to reflex
test specimens within the “low positive” index value range of
1.1 to 3.5 using an interfering factors screen (IFS) which
allowed for the subtraction of background absorbance. This
IFS would detect possible IF that may consist of either natural
antibodies or autoantibodies, including heterophile antibodies
(HA), Forrsman antibodies, rheumatoid factor (RF), and
other interfering substances (3, 4, 5, 7, 8, 11, 13, 16).
Between 1 August and 31 October 2003, automated testing
of 10,887 specimens, consisting of 10,371 serum and 516 CSF
specimens, was performed on a MAGO Plus automated en-
zyme immunoassay analyzer (Diamedix, Miami, FL). Serum
and CSF specimens were tested at dilutions of 1:100 and 1:2,
respectively. A total of 2,282 (21%) of the 10,887 specimens
were positive for WNV-specific IgM by the Focus Diagnostics
MAC-ELISA. The IFS was run manually on 794 of 2,282
(35%) WNV-specific IgM-positive specimens with index values
ranging from1.1 to3.5. The 794 specimens tested consisted
of 770 serum and 24 CSF specimens. A Tecan 96 PW micro-
titer plate washer (Research Triangle Park, NC) was used for
the washing steps. Optical density readings at 450 nm were
taken on a BioTek 800 UV microtiter plate reader (Winooski,
VT). A total of 52 of the 794 (6.5%) positive specimens were
found to contain IF at levels that would change qualitative test
results from “positive” to “indeterminate” once the back-
ground optical density was subtracted. These samples were
then categorized as “indeterminate” due to the high levels of
IF present.
At the conclusion of the WNV testing season, retrospective
IFS was conducted on 457 serum and 32 CSF specimens to
ascertain the distribution range of naturally occurring IF.
These specimens consisted of 126 positive (index values of
3.5), 81 equivocal, and 282 negative specimens. Of the 126
positive serum specimens tested, none were found to have IF
at a level that would change their qualitative result. IFS results
for the 81 serum specimens within the equivocal range were as
follows: 8 of 81 (10%) were negative, 13 of 81 (16%) remained
equivocal, 32 of 81 (40%) became positive, and 28 of 81 (35%)
were indeterminate. Results showed that 64 of 282 (23%) of
the negative specimens had IF present. However, qualitative
test results would not be changed for either the equivocal or
the negative specimens (14). The composite results of the IFS
performed on the 1,283 serum and CSF specimens tested are
shown in Table 1. Results indicate that the number of positive
specimens decreased from 920 to 900 (2.1%), negative speci-
mens decreased from 282 to 226 (23%), equivocal specimens
decreased from 81 to 8 (90%), and 144 (11.2%) specimens
contained IF. Although the 64 and 28 WNV-specific IgM-
negative and equivocal samples, respectively, were found to
have IF, interpretation would have remained negative or
equivocal regardless of the presence of IF found in subsequent
testing.
Of the total 1,283 samples that underwent the IFS, 80
(6.2%) specimens in the positive and equivocal ranges were
determined to contain IF. These serum specimens, when sam-
ple volumes permitted, underwent testing for HA using the
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Color Slide II mononucleosis test (Monospot; Seradyn, India-
napolis, IN) and testing for RF using the N Latex RF assay on
the BN Prospec nephelometer (Dade Behring, Inc., Deerfield,
IL) to try to further identify and characterize the nature of the
IF present. However, testing showed that only 8 of 65 (12%)
specimens tested were positive for RF and 6 of 42 (14%)
specimens tested were positive for HA. Results are shown in
Table 2.
The PRNT was performed by the Viral and Rickettsial Dis-
ease Laboratory, California Department of Health Services,
Richmond, CA (2). Briefly, equal volumes of a standard dose
(100 PFU per 100 l) of WNV were mixed with serum speci-
mens that had been diluted at 1:20, 1:40, and 1:80. Six of 78
(8%) specimens tested were positive for neutralizing WNV
antibodies by the PRNT screen. Although these specimens
were found to contain IF, none of the six PRNT-positive spec-
imens were positive for either RF or HA. Results are shown in
Table 2.
Statistical calculations were performed using commercial
software (SPSS, Inc., Chicago, IL) (1). Combined analysis of
the testing results of the serum and CSF specimens deter-
mined the kappa value to be 0.83 (95% confidence interval,
0.80 to 0.86).
Our testing showed that the results obtained by the Focus
Diagnostics MAC-ELISA compared to those obtained by the
IFS showed minimal differences, as demonstrated by a kappa
value of 0.83. We also found that a false positivity rate of 6.5%
(52 out of 794) would have been realized in the low positives,
within the index value range of 1.1 to 3.5, during the 2003
testing season due to the presence of IF in patient specimens.
Only a small percentage of IF could be attributed to either RF
(12%) or heterophile antibodies (14%), and 8% of the serum
specimens containing IF were also found to have neutralizing
antibody for WNV.
Our prospective and retrospective study data agreed well
with the testing results obtained at the Focus Diagnostics ref-
erence laboratory and other clinical laboratories (9, 10, 12, 15).
If one considers the fact that none of the “high positives”
(index value of 3.5) tested in the retrospective study were
found to have IF, only an overall 2.3% false positivity rate
could have been projected.
The NPHL has continued use of the IFS for reflex testing of
WNV-specific IgM-positive specimens since the 2003 season,
and the IFS is also included in the standard Focus WNV IgM
ELISA kit. Specimens found to have IF and hence causing the
qualitative results to change from positive to equivocal or neg-
ative are reported to be negative.
This study was made possible through a coordinated team effort
involving staff at the University of Nebraska Medical Center, Regional
Pathology Associates Client Services, the Nebraska Medical Center
Clinical Microbiology Department, and the NPHL. The NPHL thanks
Focus Diagnostics for providing consultation on testing methodology
and for the MAC-ELISA reagent kits used for the background sub-
traction assay during the 2003 season.
This research was partially funded by Nebraska Health and Human
Services System Regulation and Licensure.
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